-
公开(公告)号：US20180355064A1
公开(公告)日：2018-12-13
申请号：US15984822
申请日：2018-05-21
发明人： Stanislas BLEIN , Romain OLLIER , Darko SKEGRO , Samuel HOU
CPC分类号： C07K16/468 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/32 , C07K16/4291 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/526 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
-
公开(公告)号：US20180112011A1
公开(公告)日：2018-04-26
申请号：US15524482
申请日：2015-05-06
发明人： Romain OLLIER
CPC分类号： C07K16/468 , C07K16/2803 , C07K16/2809 , C07K16/2863 , C07K16/2878 , C07K16/2887 , C07K16/2896 , C07K16/32 , C07K16/4291 , C07K2317/14 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/526 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/71 , C07K2317/73 , C07K2317/92 , C07K2317/94
摘要： The present invention describes novel hetero-dimeric immunoglobulins or fragments thereof which bind to CD3 and a disease associated antigen. These hetero-dimeric immunoglobulins have been engineered to promote hetero-dimer formation during expression and can be purified to a high degree using a Protein A differential purification technique.
-
公开(公告)号：US20180094077A1
公开(公告)日：2018-04-05
申请号：US15597566
申请日：2017-05-17
发明人： Stanislas BLEIN , Darko Skegro , Paul Wassmann
CPC分类号： C07K16/46 , C07K16/18 , C07K16/2803 , C07K16/2842 , C07K16/2863 , C07K16/32 , C07K16/468 , C07K2317/50 , C07K2317/52 , C07K2317/526 , C07K2317/55 , C07K2317/622 , C07K2317/94 , C07K2319/00
摘要： The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
-
公开(公告)号：US20170350886A1
公开(公告)日：2017-12-07
申请号：US15121819
申请日：2015-03-02
IPC分类号： G01N33/569 , C07K16/00 , C12N15/85 , G01N33/68 , C12P21/00
CPC分类号： G01N33/56966 , C07K14/705 , C07K16/00 , C07K2317/31 , C07K2317/52 , C07K2317/622 , C12N15/1037 , C12N15/85 , C12N2830/42 , C12N2830/50 , C12P21/00 , G01N33/6854
摘要： The invention relates to an expression construct for the soluble expression of polypeptides in host cells and for the expression of polypeptides on the surface of host cells, using alternative splicing. The amount of cell membrane expression of polypeptides such as antibodies, antibody fragments and bispecific antibodies can be correlated directly to the amount of soluble polypeptide expressed. In the case of bispecific antibodies, cell membrane expression of heterodimer and homodimer products can be correlated directly to the soluble expression of these products, thereby aiding selection of a desired producer clone.
-
公开(公告)号：US09683053B2
公开(公告)日：2017-06-20
申请号：US14167712
申请日：2014-01-29
发明人： Stanislas Blein , Darko Skegro , Paul Wassmann
CPC分类号： C07K16/46 , C07K16/18 , C07K16/2803 , C07K16/2842 , C07K16/2863 , C07K16/32 , C07K16/468 , C07K2317/50 , C07K2317/52 , C07K2317/526 , C07K2317/55 , C07K2317/622 , C07K2317/94 , C07K2319/00
摘要： The present invention relates to engineered hetero-dimeric immunoglobulins or fragments thereof and methods of making the same.
-
公开(公告)号：US09186360B2
公开(公告)日：2015-11-17
申请号：US13495271
申请日：2012-06-13
申请人： Neelima Khairatkar-Joshi , Abhay Kulkarni , Indranil Mukhopadhyay , Vidya Ganapati Kattige , Vikram Mansingh Bhosale , Dinesh Pradeep Wale , Abraham Thomas , Sukeerthi Kumar , Sachin Sundarlal Chaudhari
发明人： Neelima Khairatkar-Joshi , Abhay Kulkarni , Indranil Mukhopadhyay , Vidya Ganapati Kattige , Vikram Mansingh Bhosale , Dinesh Pradeep Wale , Abraham Thomas , Sukeerthi Kumar , Sachin Sundarlal Chaudhari
IPC分类号： A61K31/519 , A61K31/517 , A61K31/15 , A61K31/675 , A61K31/522
CPC分类号： A61K31/522 , A61K31/15 , A61K31/517 , A61K31/519 , A61K31/675
摘要： The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.
摘要翻译： 本专利申请涉及使用TRPA1拮抗剂治疗呼吸障碍。 特别地，本专利申请涉及使用TRPA1拮抗剂治疗呼吸障碍，其中TRPA1拮抗剂通过吸入途径施用于有需要的受试者。
-
公开(公告)号：US20140341892A1
公开(公告)日：2014-11-20
申请号：US14281101
申请日：2014-05-19
发明人： Elias LAZARIDES , Catherine Woods , Mark Bernard
IPC分类号： C07K16/28 , G01N33/68 , C07K14/705 , A61K39/395 , A61K47/48
CPC分类号： C07K16/2842 , A61K39/3955 , A61K47/6849 , A61K2039/505 , C07K14/7055 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C07K2319/00 , G01N33/6872 , G01N33/6893 , G01N2333/7055
摘要： The invention relates to anti-α2 integrin antibodies and their uses. Humanized antibodies are disclosed that bind to the I domain of α2 integrin and inhibit the interaction of α2β1 integrin with collagen. Also disclosed are therapeutic uses of anti-α2 integrin antibodies in treating α2β1-mediated disorders, including anti-α2 integrin antibodies that bind to α2 integrin without activating platelets.
摘要翻译： 本发明涉及抗α2整联蛋白抗体及其用途。 公开了与α2整联蛋白的I结构域结合并抑制α2和bgr1整联蛋白与胶原蛋白相互作用的人源化抗体。 还公开了抗α2整联蛋白抗体治疗α2和bgr1介导的病症的治疗用途，包括结合α2整联蛋白而不激活血小板的抗α2整联蛋白抗体。
-
公开(公告)号：US20140294824A1
公开(公告)日：2014-10-02
申请号：US14222421
申请日：2014-03-21
IPC分类号： C07K16/28
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/53 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/70578
摘要： The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
摘要翻译： 本发明涉及与人OX40结合的拮抗剂抗体或其片段。 更具体地，本发明涉及与人OX40结合的拮抗剂抗体或其片段，其包含包含SEQ ID NO：1的氨基酸序列的重链CDR1和/或包含SEQ ID NO：1的氨基酸序列的重链CDR2 ID NO：2，和/或包含SEQ ID NO：3的氨基酸序列的重链CDR3; 和/或包含包含SEQ ID NO：4的氨基酸序列的轻链CDR1和/或包含SEQ ID NO：5的氨基酸序列的轻链CDR2和/或包含氨基酸序列的轻链CDR3 的SEQ ID NO：6。
-
公开(公告)号：US08748585B2
公开(公告)日：2014-06-10
申请号：US13545708
申请日：2012-07-10
IPC分类号： C07K16/00 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2878 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/53 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N2333/70578
摘要： The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
摘要翻译： 本发明涉及与人OX40结合的拮抗剂抗体或其片段。 更具体地，本发明涉及与人OX40结合的拮抗性抗体或其片段，其包含包含SEQ ID NO：1的氨基酸序列的重链CDR1和/或包含SEQ ID NO：1的氨基酸序列的重链CDR2 ID NO：2，和/或包含SEQ ID NO：3的氨基酸序列的重链CDR3; 和/或包含包含SEQ ID NO：4的氨基酸序列的轻链CDR1和/或包含SEQ ID NO：5的氨基酸序列的轻链CDR2和/或包含氨基酸序列的轻链CDR3 的SEQ ID NO：6。
-
公开(公告)号：US08592398B2
公开(公告)日：2013-11-26
申请号：US13327128
申请日：2011-12-15
申请人： Sukeerthi Kumar , Abraham Thomas , Sachin Sundarlal Chaudhari , Bipin Parsottam Kansagra , Venkata Ramana Yemireddy , Neelima Khairatkar-Joshi , Indranil Mukhopadhyay , Girish Gudi
发明人： Sukeerthi Kumar , Abraham Thomas , Sachin Sundarlal Chaudhari , Bipin Parsottam Kansagra , Venkata Ramana Yemireddy , Neelima Khairatkar-Joshi , Indranil Mukhopadhyay , Girish Gudi
IPC分类号： A01N57/00 , A01N43/78 , A61K31/675 , A61K31/67 , A61K31/535 , A61K31/425 , C07D277/00
CPC分类号： C07F9/6561 , C07D487/04 , C07D491/04 , C07D491/048 , C07D495/04 , C07D513/04 , C07F9/65616
摘要： The present invention is related to 2-amino-4-arylthiazole derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
-
-
-
-
-
-
-
-
-
搜索结果
143 条记录 (耗时 0.053 秒)
